By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – French biotech firm IntegraGen today announced that its first-half revenues increased 67 percent year over year driven by demand for its genomic services.

For the half-year, revenues rose to €2.5 million ($3.4 million) from €1.5 million a year ago, resulting in a 32 percent improvement in its net loss to €890,000, compared to €1.3 million a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.